News | July 02, 2022
Ardelyx gets into $20 million financing agreement with HealthCare Royalty Partners
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
The plan is to advance innovative therapies to drug-resistant cancers
Appoints Dr Rafiq Hasan as CEO
The bank will provide a complete range of financing options including hospitals, labs, diagnostic centres and equipment manufacturers
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
Following the completion of the acquisition on June 3, Noctrix’s flagship product, Nidra will become part of ResMed’s broader sleep medicine portfolio
Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier
The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
The country’s strength lies not just in technology availability but in adoption behaviour
Subscribe To Our Newsletter & Stay Updated
